Prostate Cancer Clinical Trials in Washington

Showing 121-140 of 209 trials

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

NCT02985021

In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.

Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more

Seattle Institute for Biomedical and Clinical Research2 participantsStarted Nov 2016

Los Angeles, California, United States • Ann Arbor, Michigan, United States • Seattle, Washington, United States

COMPLETEDPhase 242 miles

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

NCT01615120

Protocol G200712 is a Phase II, exploratory study to assess the effects of GTx-758 on serum prostate specific antigen (PSA) response ans serum PSA progression in men with Metastatic Castration Resistant Prostate Cancer (mCRPC) on Androgen Deprivation Therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or orchidectomy. This study will also assess the venous thromboembolism (VTE) risk of lower doses of GTx-758.

Prostate Cancer

GTx77 participantsStarted Aug 2012

Burbank, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +23 more locations

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Prostate Cancer Trials in Other Cities

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Multi-Institutional Registry for Prostate Cancer Radiosurgery

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

Firmagon (Degarelix) Intermittent Therapy

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Other Conditions in Washington